Peptic ulcer disease: Paradigms lost

Mount Sinai Journal of Medicine

Volumn 63, Issue 5-6, 1996, Pages 387-398

  Sarner, Andrea ^b   Babyatsky, Mark W ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIULCER AGENT; BISMUTH; BISMUTH SALICYLATE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; SOMATOSTATIN; SUCRALFATE; TETRACYCLINE;

GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; PEPTIC ULCER; PROSTAGLANDINS;

EID: 0029846468     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (177)

1. Kurata JH, Haile BM. Epidemiology of peptic ulcer disease. Clin Gastroenterol 1984; 13:289-292.
2. Isenberg JI, McQuaid KR, Laine L, Walsh JH. Acid-peptic disorders. In: Yamada T, editor. Textbook of gastroenterology. Philadelphia: Lippincott, 1995: 1347-1430.
3. Schwartz K. Uber penetrierende magen-und jejunal geshcwure. Beitr Klin Chir 1910; 76:96-128.
4. Black JW, Duncan WAM, Durant GJ, et al. Definition and antagonism of histamine H2-receptors. Nature 1972; 236:385-388.
5. Bardhan KD, Thompson M, Bose K, et al. Combined anti-muscarinic and H2-receptor blockade in the healing of refractory duodenal ulcer. A double blind study Gut 1987; 28:1505-1512.
6. Blair AJ III, Feldman M, Barnett C, et al. Detailed comparison of basal and food-stimulated gastric acid secretion rates and serum gastrin concentrations in duodenal ulcer patients and normal subjects. J Clin Invest 1987; 79:582-590.
7. Samloff IM. Peptic ulcer: the many proteinases of aggression. Gastroenterology 1989; 96(Suppl):586-595.
8. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322:909-917.
9. Robert AR, Schultz JR, Nezamis JE, et al. Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2 and 16,16-dimethyl PGE2 intravenous, oral and intrajejunal administration. Gastroenterology 1976; 70:359-368.
10. Robert A, Nezamis JE, Phillips JP. Effect of prostaglandin E1 on gastric secretion and ulcer formation in the rat. Gastroenterology 1968; 55:481-487.
11. Robert Andre: Cytoprotection by prostaglandins. Gastroenterology 1979; 77:761-767.
12. Lacy ER, Ito S. Microscopic analysis of ethanol damage to rat gastric mucosa after treatment with prostaglandins. Gastroenterology 1982; 83:619-625.
13. Silen W. What is cytoprotection of the gastric mucosa? Gastroenterology 1988; 94:232-235.
14. Konturek SJ. Mechanisms of gastroprotection. Scand J Gastroenterol 1990; 25(Suppl 174): 15-28.
15. Bickel M, Kauffman GL. Gastric gel mucus thickness: Effect of distention, 16,16-dimethyl prostaglandin E2, and carbenoxolone. Gastroenterology 1981; 80:770-778.
16. McQueen S, Hutton D, Allen A, et al. Gastric and duodenal surface mucus gel thickness in rat: effects of prostaglandins and damaging agents. Am J Physiol 1983; 245:388-395.
17. Bolton JP, Cohen MM. Stimulation of non-parietal cell secretion in canine Heidenhain pouches by 16,16-dimethyl prostaglandin E2. Digestion 1978; 17:291-298.
18. Kauffman GL, Reeve JJ, Grossman MI. Gastric bicarbonate secretion: effect of topical and intravenous 16,16-dimethyl prostaglandin E2. Am J Physiol 1980; 239:44-49.
19. Gerber JG, Neis AS. Canine gastric mucosal vasodilation with prostaglandins and histamine analogs. Dig Dis Sci 1982; 27:870-878.
20. Main IHM, Whittle BJR. The effects of E and A prostaglandins on gastric mucosal blood flow and acid secretion in the rat. Br J Pharmacol 1973; 49:428-435.
21. Raud J. Vasodilatation and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell-dependent inflammation. Br J Pharmacol 1990; 90:449-454.
22. Hogaboam CM, Bissonnette EY, Chin BC, et al. Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology 1993; 104:122-129.
23. Ferguson WW, Demonds AW, Starling JR, et al. Protective effect of prostaglandin E1 (PGE1) on lysosomal enzyme release in serotonin-induced gastric ulceration. Ann Surg 1973; 177:643.
24. Guth PH, Paulsen G, Nagata H. Histologic and microcirculatory changes in alcohol-induced gastric lesions in the rat: effect of prostaglandin cytoprotection. Gastroenterology 1984; 87:1083-1090.
25. Gryglewsin RJ, Szczklik A, Wandzilak M. The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymozan or formyl-leucyl-phenylalanine. Biochem Pharmacol 1987; 36: 4209-4218.
26. 4 release from activated neutrophils. Proc Natl Acad Sci USA 1983; 80: 4349-4353.
27. Svanes K, Critchlow J, Takewchi K, et al. Factors influencing reconstitution of frog gastric mucosa: role of prostaglandins. In: Allen A, Flemstrom G, Garner A, Silen W, Turnberg LA, editors. Mechanisms of mucosal protection in the upper gastrointestinal tract. Raven Press: New York, 1984: 33-38.
28. Ito S, Lacy ER. Morphology of rat gastric mucosal damage, defense and restitution in the presence of luminal ethanol. Gastroenterology 1985; 88:250-260.
29. Allen A. The structure and function of gastrointestinal mucus. In: Harmon JW, editor. Basic mechanisms of gastrointestinal mucosal cell injury and protection. Baltimore: Williams and Wilkins, 1981: 351-367.
30. Silberberg A, Meyer FA, Gilboa A, Gelman RE. Function and properties of epithelial mucus. In: Elstein M, Parke DV, editors. Mucus in health and disease. New York: Plenum Press, 1977: 171-180.
31. Bahari HMM, Ross IN, Turnberg LA. Demonstration of a pH gradient across the mucus layer on the surface of human gastric mucosa in vitro. Gut 1982; 23:513-516.
32. Bhaskar KR, Garik P, Turner BS, et al. Viscous fingering of HCl through gastric mucin. Nature 1992; 360: 458-461.
33. Fabry TL. How parietal secretion crosses the gastric mucus without being neutralized. Gastroenterology 1990; 98:A42.
34. Hills BA, Butler BD, Lichtenberger LM. Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach. Am J Physiol 1983; 244:G561-G568.
35. Butler BD, Lichtenberger LM, Hills BA. Distribution of surfactants in the canine gastrointestinal tract and their ability to lubricate. Am J Physiol 1983; 244: G645-G651.
36. Lugea A, Mourelle M, Guarner F, et al. Phosphatidylcholines as mediators of adaptive cytoprotection of the rat duodenum. Gastroenterology 1994; 107:720-727.
37. Davenport HW. Gastric mucosal injury by fatty and acetylsalicylic acid. Gastroenterology 1965; 46:245-253.
38. Davenport HW. Ethanol damage to canine oxyntic glandular mucosa. Proc Soc Exp Biol Med 1967; 126:657-662.
39. Davenport HW. Salicylate damage to the gastric mucosal barrier. N Engl J Med 1967; 276:1307-1312.
40. Allen A, Flemstrom G, Garner A, Kivilaakso E. Gastroduodenal mucosal protection. Physiol Rev 1993; 73: 823-857.
41. Silen W, Ito S. Mechanisms for rapid reepithelialization of the gastric mucosal surface. Annu Rev Physiol 1985; 47:217-229.
42. Lacy ER, Ito S. Ethanol-induced insult to superficial rat gastric epithelium: a study of damage and rapid repair. In: Allen A, editor. Mechanisms of mucosal protection in the upper gastrointestinal tract. New York: Raven Press, 1984: 49-56.
43. Rutten MJ, Ito S. Morphology and electrophysiology of guinea pig gastric mucosal repair in vitro. Am J Physiol 1983; 244:G171-G182.
44. Svanes K, Ito S, Takeuchi K, Silen W. Restitution of the surface epithelium of the in vitro frog gastric mucosa after damage with hyperosmolar sodium chloride. Morphological and physiological characteristics. Gastroenterology 1982; 82:1409-1426.
45. Dignass A, Lynch-Devaney K, Kindon H, et al. Trefoil peptides promote epithelial migration through a transforming growth factor β-independent pathway. J Clin Invest 1994; 94:376-383.
46. Dignass A, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor β. Gastroenterology 1993; 105: 1323-1332.
47. Folkman J, Szabo S, Stovroff M, et al. Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg 1991; 214:414-426.
48. Folkman J, Szabo S, Vattay P, et al. Effect of orally administered bFGF on healing of chronic duodenal ulcers, gastric secretion and acute mucosal lesions. Gastroenterology 1990; 98:A45.
49. Heitz PU, Kasper M, Van Noorden S, et al. Immunohistochemical localization of urogastrone to human duodenal and submandibular glands. Gut 1978; 19:408-413.
50. Beauchamp RD, Barnard JA, McCutchen CM, et al. Localization of transforming growth factor alpha and its receptor in gastric mucosal cells: implications for a regulatory role in acid secretion and mucosal renewal. J Clin Invest 1989; 84:1017-1023.
51. Tepperman BL, Soper BD. Effect of epidermal growth factor, transforming growth factor a and nerve growth factor on gastric mucosal integrity and microcirculation in the rat. Regul Pept 1994; 50:13-21.
52. Olsen PS. Role of epidermal growth factor in gastroduodenal mucosal protection. J Clin Gastroenterol 1988; 10(Suppl 1):S146-S151.
53. Romano M, Polk WH, Awad JH, et al. Transforming growth factor alpha protection against drug-induced injury to the rat mucosa in vivo. J Clin Invest 1992; 90:2409-2421.
54. Jeffrey G, Oates P, Wang T, et al. Spasmolytic polypeptide: a trefoil peptide secreted by rat gastric mucosal cells. Gastroenterology 1994; 106:336-345.
55. Sueomori S, Lynch-Devaney K, Podolsky DK. Identification and characterization of rat intestinal trefoil factor: tissue and cell-specific member of the trefoil protein family. Proc Natl Acad Sci USA 1991; 88:11017-11021.
56. Babyatsky MW, de Beaumont M, Thim L, Podolsky DK. Oral trefoil peptides protect against ethanol and indomethacin-induced gastric injury in rats. Gastroenterology (in press).
57. Szelenyi I, Brune K. Possible role of sulfhydryls in mucosal protection induced by aluminum hydroxide. Dig Dis Sci 1986; 31:1207-1210.
58. Szabo S, Trier JS, Frankel PW. Sulfhydryl compounds may mediate gastric cytoprotection. Science 1981; 214: 200-202.
59. Whittle BJR, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 1990; 99:607-611.
60. Morales RE, Johnson BR, Szabo S. Endothelin induces vascular and mucosal lesions, enhances the injury by HCl/ethanol, and the antibody exerts gastroprotection. FASEB J 1992; 6:2354-2360.
61. Gannon B, Browning J, O'Brien P, Rogers P. Mucosal microvascular architecture of the fundus and body of human stomach. Gastroenterology 1984; 86:866-875.
62. Yoshida N, Granger DN, Evans DJ Jr, et al. Mechanisms involved in Helicobacter pylori-induced inflammation. Gastroenterology 1993; 105:1431-1440.
63. Yoshida N, Takemura T, Granger DN, et al. Molecular determinants of aspirin-induced neutrophil adherence to endothelial cells. Gastroenterology 1993; 105:715-724.
64. Forster ER, Dockray GJ. The role of calcitonin gene-related peptide in gastric mucosal protection in the rat. Exp Physiol 1991; 76:623-626.
65. Pabst MA, Schoninkle E, Holzer P. Ablation of capsaicin sensitive afferent nerves impairs defense but not rapid repair of rat gastric mucosa. Gut 1993; 34:897-903.
66. Diel F, Szabo S. Dose-dependent effects of linear and cyclic somatostatin on ethanol-induced gastric erosions: the role of mast cells and increased vascular permeability in the rat. Regul Pept 1986; 13:235-243.
67. Karmeli F, Eliakim R, Okon E, Rachmilewitz D. Somatostatin effectively prevents ethanol- and NSAID-induced gastric mucosal damage in rats. Dig Dis Sci 1994; 39:617-625.
68. Babyatsky MW, Brand SJ, Karmeli F, et al. Enhanced somatostatin expression modulates gastric injury and experimental colitis. Gastroenterology 1993; 104: A663.
69. Yamada Y, Post S, Wang K, et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 1993; 90:4196-4200.
70. Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993; 16:34-38.
71. Lewin MJ. The somatostatin receptor in the GI tract. Annu Rev Physiol 1992; 54:455-468.
72. Reubi JC. Somatostatin receptors in the gastrointestinal tract in health and disease. Yale J Biol Med 1992; 65:493-503.
73. Scicchitano R, Bienenstock J, Stanisz AM. The differential effect with time of neuropeptides on the proliferative responses of murine Peyer's patches and splenic lymphocytes. Brain Behav Immunol 1987; 1:231-237.
74. Payan DG, Hess CA, Goetzl EJ. Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts. Cell Immunol 1984; 84:433-438.
75. Van Hugen PM, Krenning EP, Kwekkeboom DJ, et al. Somatostatin and the immune and haematopoietic system: a review. Eur J Clin Invest 1994; 24:91-99.
76. Schoen RT, Vender RJ. Mechanisms of nonsteroidal antiinflammatory drug-induced gastric damage. Am J Med 1989; 86:449-458.
77. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28:686-692.
78. Semble EL, Wu WC. Antiinflammatory drugs and gastric mucosal damage. Semin Arthritis Rheum 1987; 16.271-286.
79. Fries JF, Williams CA, Bloch DA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91:213-222.
80. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114:257-263.
81. Nonsteroidal anti-inflammatory drugs and serious gastrointestinal adverse reaction. Br Med J 1986; 292: 614-623.
82. Langman MJS. Epidemiologic evidence on the association between peptic ulceration and anti-inflammatory drug use. Gastroenterology 1989; 96:640-646.
83. Piper JM, Daugherty WA, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735-740.
84. Levi S, Shaw-Smith C. Non-steroidal anti-inflammatory drugs: how do they damage the gut? Br J Rheum 1994; 33:605-612.
85. Graham DY, Smith JL, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci 1983; 28:1-6.
86. Chaudhury TK, Robert A. Prevention by mild irritants of gastric necrosis produced in rats by sodium taurochholate. Dig Dis Sci 1980; 25:830-836.
87. Lacy ER, Cowart KS, Hund P. Effects of chronic superficial injury on the rat gastric mucosa. Gastroenterology 1992; 103:1179-1191.
88. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153-1158.
89. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med 1994; 96:274-281.
90. Bjarnason I, Hayllar J, MacPherson A, Russell AS. Side effects of NSAIDs on the small and large intestine in humans. Gastroenterology 1993; 104:1832-1847.
91. Baskin WN, Ivey KJ, Krausz WJ, et al. Aspirin-induced ultrastructural changes in human gastric mucosa. Ann Int Med 1976; 85:229-303.
92. Whittle BJR. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981; 80:94-98.
93. Kauffman G. Aspirin-induced gastric mucosal injury: lessons learned from animal models. Gastroenterology 1989; 96:606-614.
94. Levi S, Shaw-Smi C. Non-steroidal anti-inflammatory drugs: how do they damage the gut? Br J Rheumatol 1994; 33:605-612.
95. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231:232-235.
96. Whittle BJR, Vane JR. A biochemical basis for the gastrointestinal toxicity of nonsteroidal antirheumatoid drugs. Arch Toxicol 1984; 7:315-322.
97. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicenter, double-blind, placebo-controlled trial. Lancet 1988; 2:1277-1280.
98. McCarthy DM. Misoprostol. Drug Ther 1989; 19:59-69.
99. Lanza FL, Aspinall RL, Swabb EA, et al. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology 1988; 95:289-294.
100. O'Laughlin JC, Silvoso GR, Ivey KJ, Healing of aspirin-associated peptic ulcer disease despite continued salicylate ingestion. Arch Intern Med 1981; 141:781-783.
101. Berkowitz JM, Adler SN, Sharp JT, Warner CW. Reduction of aspirin-induced gastroduodenal mucosal damage with ranitidine. J Clin Gastroenterol 1986; 8:377-380.
102. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989; 34:424-428.
103. Caldwell JR, Roth SW, Wu WC, et al. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med 1987; 83:74-82.
104. McCarthy DM. Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies. Gastroenterology 1989; 96(Suppl):662-674.
105. Lanza F, Peace K, Gustitus L, et al. A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol 1988; 83:143-146.
106. Godwin CS, Worsley BW. Microbiology of Helicobacter pylori. Gastroenterol Clin North Am 1993; 22:5-18.
107. Bizzozero G. Uber die schlauchformigen drusen des magendarmkanals und die beziehungen ihres epithels zu dem oberfachenepithel der schleimhaut. Arch Mikrobiol Anat 1892; 42:82-152.
108. Krienitz W. Ueber das auftreten von spirochaten verschiedener form im mageninhalt bei carcinoma ventriculi. Deutsch Med Wochenschr 1906; 28:872.
109. Rosenow EC, Sanford AH. The bacteriology of ulcer of the stomach and duodenum in man. J Infect Dis 1915; 17:219-226.
110. Appelmans R, Vassiliadis P. Etude sur la flore microbienne des ulceres gastroduodenaux et des cancers gastriques. Rev Belge Sci Med 1932; 4:198-203.
111. Freedburg AS, Barron LE. The presence of spirochetes in human gastric mucosa. Am J Dig Dis 1940; 7:443-445.
112. Doenges JL. Spirochetes in the gastric glands of Macacus rhesus and humans without definite history of related disease. Proc Soc Exp Med Biol 1938; 38:536-538.
113. Palmer ED. Investigation of the gastric mucosa spirochetes of the human. Gastroenterology 1954; 27:218-220.
114. Lieber CS, Lefevre A. Ammonia as a source of gastric hypoacidity in patients with uremia. J Clin Invest 1959; 38:1271-1277.
115. Marshall BJ. Unidentified curved bacilla in gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-1275.
116. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1:1311-1315.
117. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfill Koch's postulates for pylorie Campylobacter. Med J Aust 1985; 142:436-439.
118. Taylor DN, Blasser MJ. The epidemiology of Helicobacter pylori infections. Epidemiol Rev 1991; 13:42-59.
119. Graham D, Go M. Helicobacter pylori: current status. Gastroenterology 1993; 105:279-282.
120. Haruma K, Kawaguchi H, Kohmoto K, et al. Reduced incidence of Helicobacter pylori in Japan during the last 10 years. Gastroenterology 1994; 106:A91.
121. Malaty HM, Engstrand L, Pedersen NL, Graham DY. Helicobacter pylori infection: genetic and environmental influences. Ann Intern Med 1994; 120:982-986.
122. Megraud F. Transmission of Helicobacter pylori: fecal-oral versus oral-oral route. Aliment Pharmacol Ther 1995; 9(Suppl 2):85-91.
123. Thomas JE, Gibson GR, Darboe MK, et al. Isolation of Helicobacter pylori from human faeces. Lancet 1992; 340:1194-1195.
124. Krajden S, Fuska M, Anderson J, et al. Examination of human stomach biopsies, saliva and dental plaque for Campylobacter pylori. J Clin Microbiol 1989; 27:1397-1398.
125. Shames B, Krajden S, Fuksa M, et al. Evidence for the occurrence of the same strain of Campylobacter pylori in the stomach and dental plaque. J Clin Microbiol 1989; 27:2849-2850.
126. Nguyen AH, Engstrand L, Genta RM, et al. Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction. J Clin Microbiol 1993; 31:783-787.
127. Fox JG. Non-human reservoirs of Helicobacter pylori. Aliment Pharmacol Ther 1995; 9(Suppl 2):93-103.
128. Bayerdorffer E, Lehn N, Hatz R, et al. Difference in expression in Helicobacter pylori gastritis in antrum and body. Gastroenterology 1992; 102:1575-1582.
129. Alam K, Schubert TT, Bologna SD, Ma CK. Increased density of Helicobacter pylori on antral biopsy is associated with severity of acute and chronic inflammation and likelihood of duodenal ulceration. Am J Gastroenterol 1992; 87:424-428.
130. Satoh K, Kimura K, Yoshida Y, et al. A topographical relationship between Helicobacter pylori and gastritis: quantitative assessment of Helicobacter pylori in the gastric mucosa. Am J Gastroenterol 1991; 86:285-291.
131. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raises fasting gastric pH. Am J Gastroenterol 1987; 82:192-197.
132. Marchetti M, Arico B, Burroni D, et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995; 267:1655-1658.
133. Fukuda Y, Tamura K, Yamamoto I, et al. Inoculation of rhesus monkeys with human Helicobacter pylori: a long-term investigation on gastric mucosa by endoscopy. Dig Endoscopy 1992; 4:19-30.
134. Fujioka T, Shuto R, Kodama R, et al. Experimental model for chronic gastritis with Helicobacter pylori: long-term follow-up study in H. Pylori-infected Japanese macaques. Eur J Gastroenterol Hepatol 1993; 5(Suppl 1):S73-S75.
135. Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161: 626-633.
136. Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9(Suppl 2):59-69.
137. Seppala K. H pylori and gastric ulcer disease. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori. Basic mechanisms to clinical cure. Dordrecht, Netherlands: Kluwer Academic, 1994: 429-436.
138. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann Intern Med 1992; 116:705-708.
139. Hentschel E, Brandstatter G, Dragasics B, et al. Effect of ranitidine and amoxacillin plus metronidazole in the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328:308-312.
140. Vaira D, Miglioli M, Mule P, et al. Prevalence of peptic ulcer in Helicobacter pylori positive blood donors. Gut 1994; 35:309-312.
141. Sipponon P, Varis K, Fraki O, et al. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. Scand J Gastroenterol 1990; 25:966-973.
142. Figura N, Guglielmetti P, Rossolini A, et al. Cytotoxin production by Campylobacter pylori strains from patients with peptic ulcers and patients with chronic gastritis only. J Clin Microbiol 1989; 27.225-226.
143. Goossens H, Glupczynski Y, Burette A, et al. Role of the vacuolating toxin from Helicobacter pylori in the pathogenesis of duodenal and gastric ulcer. Med Microbiol Lett 1992; 1:153-159.
144. Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993; 5:695-699.
145. Oderda G, Figura N, Bayeli PF, et al. Serologic IgG recognition of Helicobacter pylori cytotoxin associated protein, peptic ulcer and gastroduodenal pathology in childhood. Eur J Gastroenterol Hepatol 1993; 5:695-699.
146. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333:984-991.
147. Martin DF, Montgomery E, Dobeck AS, et al. Campylobacter, NSAIDs, and smoking: risk factors for peptic ulcer disease. Am J Gastroenterol 1989; 84:1268-1272.
148. Riccardi VM, Rotter JI. Familial Helicobacter pylori infection. Societal factors, human genetics, and bacterial genetics. Ann Intern Med 1994; 120:982-986.
149. Boren T, Falk P, Roth KA, et al. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993; 262:1892-1895.
150. Hook-Nikanen J, Sipponen P, Kosunen TU. Effect of ABO blood group and secretor status on the frequency of Helicobacter pylori antibodies. Scand J Gastroenterol 1990; 25:815-818.
151. Azuma T, Konishi J, Tanaka Y, et al. Contribution of HLA-DQA gene to host's response against Helicobacter pylori. Lancet 1994; 343:542-543.
152. Calam J. Helicobacter pylori, acid, and gastrin. Eur J Gastroenterol Hepatol 1995; 7:310-317.
153. Graham DY, Opekun A, Lew GM, et al. Helicobacter pylori- associated exaggerated gastrin release in duodenal ulcer patients. The effect of bombesin infusion and urea ingestion. Gastroenterology 1991; 100:1571-1575.
154. Mulholland G, Ardill JE, Fillmore D, et al. Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17. Gut 1993; 34:757-761.
155. Moss SF, Legon S, Bishop AE, et al. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340:930-933.
156. Graham DY, Lew GM, Lechago J, Antral G-cell and D-cell numbers in Helicobacter pylori infection: effect of H. pylori eradication. Gastroenterology 1993; 104: 1655-1660.
157. Isenberg JI, Selling HA, Hogan DL, Koss MA. Impaired proximal duodenal mucosal bicarbonate secretion in patients with duodenal ulcer. N Engl J Med 1987; 316: 374-379.
158. Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol 1987; 40:841-848.
159. Marshall BJ, Warren JR, Francis GJ, et al. Rapid urease test in the management of Campylobacter pyloridis-associated gastritis. Am J Gastroenterol 1987; 82:200-210.
160. Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ. Campylobacter pylori antibodies in humans. Ann Intern Med 1988; 109:11-17.
161. Graham DY, Klein PD, Evans DJ Jr, et al. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet 1987; 1:1174-1177.
162. Marshall BJ, Plankey MW, Hoffman SR, et al. A 20-minute breath test for Helicobacter pylori. Am J Gastroenterol 1991; 86:438-445.
163. Graham DY, Evans DG, Evans DJ. Better, accurate, more rapid and convenient physician-office serologic test for detection of H. pylori infection. Gastroenterology 1994; 106:A83.
164. Kosunen TU, Seppala K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titers after eradication of Helicobacter pylori. Lancet 1992; 339:.
165. NIH Consensus Development Panel. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272:65-69.
166. Buckley M, O'Morain C. Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Aliment Pharmacol Ther 1995; 9(Suppl 2):53-58.
167. Megraud F. Rationale for the choice of antibiotics for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1995; 7(Suppl 1):S49-S54.
168. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-1727.
169. Tytgat GNJ. Treatments that impact favorably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8:359-368.
170. Labenz J, Gyenes E, Ruhl GH, Borsch G. Amoxacillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut 1993; 34:1167-1170.
171. Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxacillin to cure Helicobacter pylori infection in patients with duodenal ulcer. Gastroenterology 1995; 108:1412-1417.
172. Laine L, Stein C, Neil G. Limited efficacy of omeprazole-based dual and triple H. pylori therapy: a randomized trial employing "optimal" dosing. Gastroenterology 1995; 108:A81.
173. Hosking SW, Ling TK, Yung MY, et al. Randomised, controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. Br Med J 1992; 305:502-504.
174. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 35: 490-496.
175. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med 1992; 116:705-708.
176. Chen M, Lee A, Hazell S. Immunisation against gastric Helicobacter infection in a mouse/Helicobacter felis model. Lancet 1992; 339:1120-1121.
177. Chen M, Lee A, Hazell S, et al. Immunisation against gastric infection with Helicobacter species: first step in the prophylaxis against gastric cancer? Int J Med Microbiol Virol Parasitol Infect Dis 1993; 280:155-165.